A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods
Condition: Colorectal Cancer; Colon Adenoma
MeSH terms: Adenoma
Study type: Interventional
Phase: Phase 3

Summary: 
      Colonoscopy is a common screening method to detect polyps and CRC. With the early detection
      of CRC through screening colonoscopy, patients could have better therapeutic effects and
      outcomes. In population screening programs, an increase in completed colonoscopies is related
      to a decrease in mortality from CRC. However, the miss rate for detecting colorectal
      neoplastic polyps of colonoscopy is 5-28%. The reluctance of participants to undergo bowel
      preparation results in the relatively low rate of detection of polyps and CRC, because poor
      preparation interferes with successful colon mucosa examination during a colonoscopy.

      Low-volume bowel preparations provide equivalent cleansing effect compared with standard 4
      liter polyethylene glycol. However, studies comparing the superiority between low-volume
      bowel preparations are rare, and results are controversial. This study aimed to compare the
      bowel cleansing quality and tolerability between split-dose sodium picosulfate/magnesium
      citrate and polyethylene glycol with ascorbic acid.
    

Detailed description: 
      1. Study design: endoscopist-blinded, prospective, randomized controlled trial

        2. Subjects

             1. Entry criteria: Male or female patients, aged between18 and 80 years undergoing
                elective outpatient colonoscopy were eligible for the study.

             2. Exclusion criteria:

           patients who had chronic kidney disease, severe heart failure(New York Heart Association
           [NYHA] class III or IV), uncontrolled hypertension (systolic pressure ≥170 mm Hg,
           diastolic pressure ≥100 mm Hg), severe constipation, any bowel resection, significant
           gastroparesis, or suspected bowel obstruction or perforation.

        3. Sampling design: Consecutive recruitment of consenting patients

        4. Variables Predictor

             1. group 1 (SPMC 2) received one sachet of SPMC at 7 p.m the evening before
                colonoscopy and another sachet of SPMC at 5 hours before procedure

             2. group 2 (PEG-Asc) received 1 L solution of PEG-Asc at 7 p.m the evening before
                colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure;

        5. Primary Outcome: Quality of bowel preparation (Boston Bowel Preparation Scale, Aronchick
           scale, bubble score)

        6. Secondary Outcome: Tolerability, palatability
    

Intervention name(s): PEG-Asc; SPMC 2
Intervention type(s): Drug; Drug
Intervention description(s): received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure; received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
Other intervention name(s): Coolprep®; TaeJoon Pharmaceuticals, Seoul, Korea; Picolight(Pharmbio korea, Seoul, Korea)
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Investigator)
Primary purpose: Supportive Care
Keywords: Bowel preparation; Polyethylene glycol with ascorbic acid; Sodium picosulfate with magnesium citrate